These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Drugs for migraine. Treat Guidel Med Lett; 2004 Sep; 2(25):63-6. PubMed ID: 15529091 [No Abstract] [Full Text] [Related]
4. [Triptans in migraine: from clinical view]. Manaka S No To Shinkei; 2004 Sep; 56(9):739-45. PubMed ID: 15552862 [No Abstract] [Full Text] [Related]
5. The discovery and development of the triptans, a major therapeutic breakthrough. Humphrey PP Headache; 2008 May; 48(5):685-7. PubMed ID: 18471110 [TBL] [Abstract][Full Text] [Related]
6. Introduction: cardiovascular safety and triptans in the acute treatment of migraine. Dodick DW Headache; 2004 May; 44 Suppl 1():S1-4. PubMed ID: 15149487 [No Abstract] [Full Text] [Related]
8. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581 [TBL] [Abstract][Full Text] [Related]
9. Importance of headache. Peatfield RC Curr Med Res Opin; 2001; 17 Suppl 1():s1-3. PubMed ID: 12463269 [No Abstract] [Full Text] [Related]
11. [Triptans in migraine: a comparative review of pharmacology, pharmacokinetics]. Kato K No To Shinkei; 2004 Sep; 56(9):733-8. PubMed ID: 15552861 [No Abstract] [Full Text] [Related]
13. New migraine drugs. Harv Womens Health Watch; 1999 Feb; 6(6):7. PubMed ID: 9973892 [No Abstract] [Full Text] [Related]
14. Coronary vasoconstrictor potential of triptans: a review of in vitro pharmacologic data. Maassen Van Den Brink A; Saxena PR Headache; 2004 May; 44 Suppl 1():S13-9. PubMed ID: 15149489 [TBL] [Abstract][Full Text] [Related]
15. Predictors of adherence to triptans: factors of sustained vs lapsed users. Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501 [TBL] [Abstract][Full Text] [Related]
17. Early triptan intervention in migraine: an overview. Moschiano F; D'Amico D; Allais G; Rigamonti A; Melzi P; Schieroni F; Bussone G Neurol Sci; 2005 May; 26 Suppl 2():s108-10. PubMed ID: 15926006 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment. Tfelt-Hansen P; Edvinsson L Cephalalgia; 2007 Oct; 27(10):1091-3. PubMed ID: 17714521 [TBL] [Abstract][Full Text] [Related]
19. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210 [TBL] [Abstract][Full Text] [Related]
20. [What takes place in the receptor? Ligand-receptor interaction in 5-HT agonists]. Gurrath M Pharm Unserer Zeit; 2002; 31(5):470-8. PubMed ID: 12369165 [No Abstract] [Full Text] [Related] [Next] [New Search]